Tandem Diabetes Care Management
Management criteria checks 2/4
Tandem Diabetes Care's CEO is John Sheridan, appointed in Apr 2013, has a tenure of 5.83 years. total yearly compensation is $8.53M, comprised of 8.6% salary and 91.4% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $1.43M. The average tenure of the management team and the board of directors is 3.8 years and 4.8 years respectively.
Key information
John Sheridan
Chief executive officer
US$8.5m
Total compensation
| CEO salary percentage | 8.6% |
| CEO tenure | 12yrs |
| CEO ownership | 0.1% |
| Management average tenure | 3.8yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
FDA Approval Of Control-IQ+ Will Expand Market Reach In Type 2 Diabetes
Mar 22 Operational improvements and new tech launches are expected to boost customer adoption and revenue, with increased market presence and margin expansion initiatives in Europe.Not Many Are Piling Into Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Stock Yet As It Plummets 40%
Feb 28
Tandem Diabetes Q4 Earnings Review: I Don't Share The Market's Skepticism
Feb 27Is There An Opportunity With Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) 47% Undervaluation?
Jan 18Is Tandem Diabetes Care (NASDAQ:TNDM) Weighed On By Its Debt Load?
Dec 27Tandem Diabetes: Recurring Value Erosion, Not Right Point In Cycle To Own
Nov 28Slammed 27% Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Screens Well Here But There Might Be A Catch
Nov 16Health Check: How Prudently Does Tandem Diabetes Care (NASDAQ:TNDM) Use Debt?
Sep 28Potential Upside For Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Not Without Risk
Aug 31Tandem Diabetes: Mobi's Surprise Sales Fail To Offset Flat Operating Margin
Aug 14Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 04Is It Time To Consider Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM)?
Jul 12Is Tandem Diabetes Care (NASDAQ:TNDM) Weighed On By Its Debt Load?
Jun 18Tandem Diabetes Care: Recent Rally Fully Deserved, Likely More Upside Here
May 29Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) 26% Jump Shows Its Popularity With Investors
May 10A Look At The Fair Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)
May 04At US$30.10, Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Worth Looking At Closely?
Mar 26Even With A 27% Surge, Cautious Investors Are Not Rewarding Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Performance Completely
Mar 08Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt In A Risky Way?
Feb 22Estimating The Intrinsic Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)
Jan 14Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Stock Rockets 63% But Many Are Still Ignoring The Company
Dec 27Is It Too Late To Consider Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM)?
Nov 12Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Intrinsic Value Is Potentially 53% Above Its Share Price
Oct 06Does Tandem Diabetes Care (NASDAQ:TNDM) Have A Healthy Balance Sheet?
Sep 17Should You Think About Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Now?
Aug 08Calculating The Intrinsic Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)
Jul 03Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt Sensibly?
Jun 13Cautious Investors Not Rewarding Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Performance Completely
May 06Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt In A Risky Way?
Jan 04Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Potentially Undervalued?
Oct 15Tandem Diabetes Care: Overpriced, Underdelivering
Sep 22An Intrinsic Calculation For Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Suggests It's 50% Undervalued
Sep 10Tandem Diabetes stock falls 10% on disappointing Q2 result
Aug 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | US$9m | US$732k | -US$96m |
| Sep 30 2024 | n/a | n/a | -US$127m |
| Jun 30 2024 | n/a | n/a | -US$136m |
| Mar 31 2024 | n/a | n/a | -US$141m |
| Dec 31 2023 | US$5m | US$711k | -US$223m |
| Sep 30 2023 | n/a | n/a | -US$208m |
| Jun 30 2023 | n/a | n/a | -US$224m |
| Mar 31 2023 | n/a | n/a | -US$204m |
| Dec 31 2022 | US$6m | US$711k | -US$95m |
| Sep 30 2022 | n/a | n/a | -US$68m |
| Jun 30 2022 | n/a | n/a | -US$13m |
| Mar 31 2022 | n/a | n/a | US$6m |
| Dec 31 2021 | US$6m | US$690k | US$16m |
| Sep 30 2021 | n/a | n/a | US$22m |
| Jun 30 2021 | n/a | n/a | US$7m |
| Mar 31 2021 | n/a | n/a | -US$25m |
| Dec 31 2020 | US$4m | US$600k | -US$34m |
| Sep 30 2020 | n/a | n/a | -US$49m |
| Jun 30 2020 | n/a | n/a | -US$42m |
| Mar 31 2020 | n/a | n/a | -US$17m |
| Dec 31 2019 | US$11m | US$500k | -US$25m |
| Sep 30 2019 | n/a | n/a | -US$24m |
| Jun 30 2019 | n/a | n/a | -US$55m |
| Mar 31 2019 | n/a | n/a | -US$113m |
| Dec 31 2018 | US$2m | US$386k | -US$123m |
Compensation vs Market: John's total compensation ($USD8.53M) is above average for companies of similar size in the US market ($USD6.08M).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
CEO
John Sheridan (69 yo)
12yrs
Tenure
US$8,526,238
Compensation
Mr. John F. Sheridan has been President and Chief Executive Officer at Tandem Diabetes Care, Inc., since March 01, 2019 and served as its Chief Operating Officer and Executive Vice President since April 20...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 12yrs | US$8.53m | 0.12% $ 1.4m | |
| Executive VP | 7.3yrs | US$2.48m | 0.059% $ 705.9k | |
| Executive VP & COO | less than a year | US$2.60m | 0.016% $ 190.3k | |
| Executive VP & Chief Administrative Officer | 11.6yrs | US$2.01m | 0.047% $ 563.3k | |
| Executive VP and Chief Strategy & Product Officer | 3.8yrs | US$2.01m | 0.028% $ 339.0k | |
| Executive VP & Chief Commercial Officer | 1.4yrs | US$802.75k | 0.036% $ 435.9k | |
| Chief Technical Officer | 3.4yrs | no data | 0.025% $ 296.1k | |
| Executive VP | 3.3yrs | no data | 0.022% $ 263.6k | |
| Chief Human Resources Officer | 7.7yrs | no data | no data | |
| Chief Medical Officer | 1.3yrs | no data | no data | |
| VP & Corporate Controller | 5.1yrs | no data | no data |
3.8yrs
Average Tenure
54.5yo
Average Age
Experienced Management: TNDM's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.8yrs | US$8.53m | 0.12% $ 1.4m | |
| Independent Chairwoman of the Board | 6.3yrs | US$343.45k | 0.014% $ 169.7k | |
| Independent Director | 11.8yrs | US$303.45k | 0.036% $ 432.9k | |
| Independent Director | 17.8yrs | US$303.27k | 0.058% $ 700.0k | |
| Independent Director | 4.7yrs | US$298.95k | 0.025% $ 301.4k | |
| Independent Director | 4.3yrs | US$294.60k | 0.017% $ 201.1k | |
| Independent Director | 4.8yrs | US$294.93k | 0.020% $ 243.2k | |
| Independent Director | 2.8yrs | US$288.45k | 0.011% $ 136.6k | |
| Independent Director | 2.8yrs | US$289.95k | 0.011% $ 136.6k |
4.8yrs
Average Tenure
60yo
Average Age
Experienced Board: TNDM's board of directors are considered experienced (4.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/28 04:20 |
| End of Day Share Price | 2025/04/25 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tandem Diabetes Care, Inc. is covered by 38 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Johnson | Baird |
| Travis Steed | Barclays |
| Matthew Miksic | Barclays |